Claims
- 1. A method for treating a disease or disorder associated with an elevated level of TNFα and/or products of COX-2 activity, comprising administering to a subject in need thereof a chemically modified tetracycline compound having negligible anti-microbial activity in an amount sufficient to reduce the expression or activity of COX-2 and/or TNFα in the subject to treat a disease or disorder associated with an elevated level of TNFα and/or products of COX-2 activity selected from the group consisting of multiple sclerosis, septic shock, graft-vs.-host disease, cerebral malaria, cachexia associated with HIV infection, brain ischemia, inflammatory bowel disease, and neurodegenerative disorders.
- 2. The method of claim 1, wherein the chemically modified tetracycline compound having negligible anti-microbial activity is selected from the group consisting of CMT-1, CMT-3, and CMT-8.
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority from U.S. provisional application serial No. 60/068,286, filed Dec. 19, 1997, the entire contents of which are hereby incorporated by reference.
US Referenced Citations (5)
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/068286 |
Dec 1997 |
US |